Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) EBITDA Margin (2017 - 2025)

Akebia Therapeutics (AKBA) has disclosed EBITDA Margin for 9 consecutive years, with 21.25% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 2780.0% to 21.25% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 2.26% through Dec 2025, up 4107.0% year-over-year, with the annual reading at 2.26% for FY2025, 4107.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 21.25% at Akebia Therapeutics, down from 0.92% in the prior quarter.
  • The five-year high for EBITDA Margin was 7474.37% in Q2 2022, with the low at 5821.83% in Q4 2021.
  • Average EBITDA Margin over 5 years is 24.51%, with a median of 53.54% recorded in 2024.
  • The sharpest move saw EBITDA Margin surged 763130bps in 2022, then crashed -749418bps in 2023.
  • Over 5 years, EBITDA Margin stood at 5821.83% in 2021, then soared by 97bps to 202.37% in 2022, then soared by 83bps to 34.46% in 2023, then plummeted by -42bps to 49.04% in 2024, then soared by 57bps to 21.25% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 21.25%, 0.92%, and 0.4% for Q4 2025, Q3 2025, and Q2 2025 respectively.